![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CGREF1 |
Gene summary for CGREF1 |
![]() |
Gene information | Species | Human | Gene symbol | CGREF1 | Gene ID | 10669 |
Gene name | cell growth regulator with EF-hand domain 1 | |
Gene Alias | CGR11 | |
Cytomap | 2p23.3 | |
Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | Q99674 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10669 | CGREF1 | HCC1_Meng | Human | Liver | HCC | 1.69e-80 | 3.46e-01 | 0.0246 |
10669 | CGREF1 | HCC1 | Human | Liver | HCC | 3.29e-07 | 2.82e+00 | 0.5336 |
10669 | CGREF1 | Pt14.a | Human | Liver | HCC | 6.84e-06 | 2.61e-01 | 0.0169 |
10669 | CGREF1 | S014 | Human | Liver | HCC | 2.07e-29 | 8.70e-01 | 0.2254 |
10669 | CGREF1 | S015 | Human | Liver | HCC | 3.09e-24 | 9.50e-01 | 0.2375 |
10669 | CGREF1 | S016 | Human | Liver | HCC | 1.35e-41 | 9.79e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CGREF1 | SNV | Missense_Mutation | novel | c.845C>T | p.Ala282Val | p.A282V | Q99674 | protein_coding | deleterious(0.04) | benign(0.031) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CGREF1 | SNV | Missense_Mutation | novel | c.279N>T | p.Glu93Asp | p.E93D | Q99674 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CGREF1 | SNV | Missense_Mutation | novel | c.493N>T | p.Ala165Ser | p.A165S | Q99674 | protein_coding | tolerated(0.69) | benign(0.026) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
CGREF1 | SNV | Missense_Mutation | novel | c.403N>G | p.Thr135Ala | p.T135A | Q99674 | protein_coding | tolerated(0.08) | possibly_damaging(0.789) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CGREF1 | SNV | Missense_Mutation | novel | c.123C>A | p.Phe41Leu | p.F41L | Q99674 | protein_coding | tolerated(0.09) | probably_damaging(0.991) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CGREF1 | SNV | Missense_Mutation | novel | c.161A>G | p.Tyr54Cys | p.Y54C | Q99674 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CGREF1 | SNV | Missense_Mutation | c.89C>A | p.Ser30Tyr | p.S30Y | Q99674 | protein_coding | deleterious(0.01) | benign(0.271) | TCGA-DD-A1EJ-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | sorafenib | PD | |
CGREF1 | SNV | Missense_Mutation | c.62N>T | p.Pro21Leu | p.P21L | Q99674 | protein_coding | deleterious(0) | benign(0.389) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
CGREF1 | SNV | Missense_Mutation | c.103N>G | p.Gln35Glu | p.Q35E | Q99674 | protein_coding | tolerated(0.24) | benign(0.039) | TCGA-93-8067-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CGREF1 | insertion | Frame_Shift_Ins | novel | c.462_463insA | p.Pro155ThrfsTer20 | p.P155Tfs*20 | Q99674 | protein_coding | TCGA-99-8033-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |